Vincent Laure

Vincent Laure

Oncologie hémato.

Hôpital Saint-Éloi
Montpellier, France

175 Activités

387 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Myélome multiple Tumeurs à plasmocytes Leucémies Tumeurs hématologiques Lymphomes Maladie du greffon contre l'hôte Récidive tumorale locale Leucémie aigüe myéloïde Maladie résiduelle

Collaborateurs

Voir plus

Oncopole Toulouse, Toulouse, France

Hôpital Lyon Sud, Pierre-Bénite, France

Cartron Guillaume

Hôpital Saint-Éloi, Montpellier, France

Hôpital La Miletrie, Poitiers, France

Industries

Voir plus

Janssen

30 collaboration(s)

Dernière en 2023

Edimark

4 collaboration(s)

Dernière en 2022

Amgen

4 collaboration(s)

Dernière en 2022

Sanofi

3 collaboration(s)

Dernière en 2023

Dernières activités

Voir plus

RHUMM: Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma RHU(M)M Random or H24 Urine in (Multiple) Myeloma

Essai Clinique (Intergroupe Francophone du Myélome) 15 mars 2024

Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia.

Blood 07 mars 2024

MonumenTAL-1: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Essai Clinique (Janssen) 27 février 2024

MajesTEC-1: A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody in Subjects With Relapsed or Refractory Multiple Myeloma

Essai Clinique (Janssen) 27 février 2024

MoMMent: A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma

Essai Clinique (Janssen) 27 février 2024

MajesTEC-1: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Essai Clinique (Janssen) 27 février 2024

MonumenTAL-1: A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Talquetamab, a Humanized GPRC5D x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma

Essai Clinique (Janssen) 27 février 2024

Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Advances in therapy 24 février 2024

Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.

Advances in therapy 19 décembre 2023

LocoMMotion: A Prospective, Multinational Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including PI, IMID, and CD38 Monoclonal Antibody Treatment

Essai Clinique (Janssen) 07 décembre 2023